Bortezomib 2 mg/mL is a specialized antineoplastic injection utilized as a potent proteasome inhibitor for treating multiple myeloma and mantle cell lymphoma. It is frequently administered subcutaneously (2.5 mg/mL) or intravenously (1 mg/mL) and works by disrupting normal cell protein degradation, leading to apoptosis of cancer cells.